Nu Skin (NUS) Receives a Buy from Pivotal Research

By Jason Carr

In a report released today, Timothy Ramey from Pivotal Research reiterated a Buy rating on Nu Skin (NUSResearch Report), with a price target of $70. The company’s shares closed yesterday at $38.54, close to its 52-week low of $35.03.

Ramey observed:

“We suspect that NUS management has taken an axe to the outlook to avoid having to cut again.”

According to, Ramey is a 4-star analyst with an average return of 5.1% and a 52.8% success rate. Ramey covers the Consumer Goods sector, focusing on stocks such as Constellation Brands Inc, Post Holdings Inc, and Brown-Forman B.

Currently, the analyst consensus on Nu Skin is a Moderate Buy with an average price target of $50.

See today’s analyst top recommended stocks >>

Based on Nu Skin’s latest earnings release for the quarter ending March 31, the company reported a quarterly net profit of $43 million. In comparison, last year the company had a net profit of $50.96 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Nu Skin Enterprises, Inc. engages in the development and distribution of beauty and wellness products and solutions. Its brands include Nu Skin and Pharmanex. The company was founded by Blake M. Roney, Sandra N. Tillotson, and Steven J. Lund in 1984 and is headquartered in Provo, UT.